Home » Gilead Sciences Partners with Gritstone Oncology for HIV Cure
Gilead Sciences Partners with Gritstone Oncology for HIV Cure
Gilead Sciences and Gritstone Oncology have teamed up to develop a vaccine-based immunotherapy to cure HIV infection.
Under the agreement, the companies will leverage Gritstone’s vaccine platform, which uses both messenger-RNA and adenovirus-based vectors, as well as antigens produced by Gilead, which will be spearheading a phase 1 study of the HIV therapeutic vaccine candidate.
Gritstone will receive $60 million upfront and is eligible to receive up to $725 million based on reaching certain development and sales-based milestones and future royalties.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May